Celyad SA (NASDAQ:CYAD) is scheduled to post its quarterly earnings results before the market opens on Tuesday, August 29th.

Celyad SA (NASDAQ CYAD) opened at 42.26 on Friday. Celyad SA has a 52 week low of $16.31 and a 52 week high of $48.93. The company’s 50-day moving average price is $39.37 and its 200 day moving average price is $34.37. The company’s market capitalization is $402.32 million.

TRADEMARK VIOLATION WARNING: “Celyad SA (CYAD) Scheduled to Post Earnings on Tuesday” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/27/celyad-sa-cyad-scheduled-to-post-earnings-on-tuesday.html.

A number of equities research analysts recently issued reports on CYAD shares. BidaskClub downgraded Celyad SA from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research report on Thursday, June 29th.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.